These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 25968608

  • 1. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.
    Orphanet J Rare Dis; 2015 May 13; 10():62. PubMed ID: 25968608
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 3. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 15; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 5. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 15; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 15; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Jul 15; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 8. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 15; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 9. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 15; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 10. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S.
    Blood Cells Mol Dis; 2009 Feb 15; 43(3):264-88. PubMed ID: 19502088
    [Abstract] [Full Text] [Related]

  • 11. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 15; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

  • 12. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 13. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.
    Machaczka M, Kämpe Björkvall C, Wieremiejczyk J, Paucar Arce M, Myhr-Eriksson K, Klimkowska M, Hägglund H, Svenningsson P.
    Arch Immunol Ther Exp (Warsz); 2015 Feb 15; 63(1):65-71. PubMed ID: 25205209
    [Abstract] [Full Text] [Related]

  • 14. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 15; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 15. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 15; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 16. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC, Schwartz IV, Lopes de Oliveira F, Alegra T, Campos Martins NL, Todeschini LA, Picon PD.
    Public Health Genomics; 2010 Dec 15; 13(1):27-33. PubMed ID: 19407439
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 15; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 18. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
    Zimran A, Altarescu G, Elstein D.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):111-4. PubMed ID: 20542712
    [Abstract] [Full Text] [Related]

  • 19. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug 15; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 20. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 15; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.